Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RCT 1100

Next Previous
X
Search
Drug Profile

RCT 1100

Alternative Names: RCT-1100

Latest Information Update: 20 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ReCode Therapeutics
  • Class Gene therapies; RNA
  • Mechanism of Action DNAI1 protein expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Primary ciliary dyskinesia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Primary ciliary dyskinesia

Most Recent Events

  • 22 Oct 2024 Phase-I clinical trials in Primary ciliary dyskinesia in Germany, Denmark (Inhalation) (NCT06633757)
  • 09 Oct 2024 ReCode Therapeutics plans a phase-I trial for Primary ciliary dyskinesia in Denmark and Germany (Inhalation), (NCT06633757)
  • 20 Sep 2024 Phase-I clinical trials in Primary ciliary dyskinesia in United Kingdom (Inhalation) (NCT06600425)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top